[100 Pages Report] Lung in vitro models are defined as cell models that represent a normal or diseased lung physiology. These cells when constructed in a monolayer on a petri plate are called 2D in vitro models. 3D models have a 3-dimensional architecture and use supports and scaffolds to maintain their structure. 3D models can be made in-house using consumables and are also available commercially as ready-to-use in vitro models.
The global in vitro lung model market was valued at USD 166.5 Million in 2017 and is expected to reach USD 427.4 Million by 2023, at a CAGR of 17.5% during the forecast period.
Download PDF Brochure:
Detailed analysis and profiling of additional market players (Up to 5)
The lung in vitro models market is projected to reach USD 427.4 Million by 2023 from USD 190.5 Million in 2018, at a CAGR of 17.5%. The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, advancements in Cell Culture technologies, and the development of new 3D in vitro models.
The report analyzes the lung in vitro models market by type, applications, and region. Based on type, the in vitro lung model market is segmented into 2D cell models and 3D cell models. 3D cell models is further segmented into in-house and commercialized 3D models (ready-to-use). The 3D cell models segment is projected to grow at the fastest rate during the forecast period due to the rising need for efficient lung in vitro models that mimic in vivo physiology.
Based on application, the market is segmented into applications of 2D models and 3D models. Applications of 2D models include drug discovery and toxicology, 3D model development, and basic research. The drug discovery and toxicology segment is expected to hold the largest share of 2D applications in 2018. The drug discovery and toxicology applications dominated the 2D application segment owing to the flexibility and high throughput capabilities of 2D cell models. Applications of 3D models include drug discovery and toxicology, physiological research, and stem cell research & regenerative medicine. The drug discovery and toxicology segment applications of 3D lung in vitro models are expected to dominate the market in 2018. The 3D cell models provide the relevant in vivo environment and reproducibility for drug discovery and toxicology applications.
The major players in the lung in vitro models market include Epithelix (Switzerland), MatTek Corporation (US), Lonza (Switzerland), ATCC (US), InSphero (Switzerland), Emulate (US), AlveoliX (Switzerland), Oncotheis (Switzerland), Insphero (Switzerland), TissUse (Switzerland), Mimetas (Netherlands), and CN Bio Innovations (UK).